Patients with secondary t-AML patients with TP53 Arg72Pro and SH2B3 W262R: A case report and review of the literature

Abstract

Abstract Background: The incidence of therapy-related acute myeloblastic leukemia (t-AML) has increased in recent years owing to advances in tumor treatment. Compared to de novo AML, patients with t-AML have a poorer response to treatment and shorter overall survival. Genetic variants are associated with the risk of developing t-AML. Case presentation: In this study, we report two cases of t-AML following treatment for diffuse large B-cell lymphoma. All the patients had previously undergone stem cell transplantation and high-dose chemotherapy. The time interval between the initial diagnosis and the onset of t-AML varied from 15 to 21 months. TP53 SNP rs1042522 and SH2B3 W262R polymorphisms were detected at baseline in both patients. Conclusions: Based on the present findings and a review of the literature, we propose that patients with the GG and GC genotypes of the SNP rs1042522 and SH2B3 W262R polymorphisms may be at a higher risk of developing t-AML.